NYSE:BAX Baxter International (BAX) Stock Price, News & Analysis $39.10 -0.27 (-0.69%) (As of 12:12 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Baxter International Stock (NYSE:BAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$39.05▼$39.7050-Day Range$33.97▼$40.2652-Week Range$31.01▼$44.01Volume841,271 shsAverage Volume4.16 million shsMarket Capitalization$19.92 billionP/E Ratio7.52Dividend Yield2.97%Price Target$41.73Consensus RatingHold Company OverviewBaxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.Read More… China Stockpiling Gold “Like No Tomorrow” (Ad)For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. Baxter International Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 89th PercentileBaxter International scored higher than 89% of companies evaluated by MarketBeat, and ranked 134th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingBaxter International has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 2 buy ratings, 8 hold ratings, and 1 sell rating.Amount of Analyst CoverageBaxter International has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Baxter International's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.11% Earnings GrowthEarnings for Baxter International are expected to grow by 8.11% in the coming year, from $2.96 to $3.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Baxter International is 7.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Baxter International is 7.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.31.Price to Earnings Growth RatioBaxter International has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBaxter International has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Baxter International's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.14% of the outstanding shares of Baxter International have been sold short.Short Interest Ratio / Days to CoverBaxter International has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Baxter International has recently increased by 24.60%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldBaxter International pays a meaningful dividend of 2.95%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthBaxter International does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Baxter International is 22.31%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Baxter International will have a dividend payout ratio of 36.25% next year. This indicates that Baxter International will be able to sustain or increase its dividend.Read more about Baxter International's dividend. Sustainability and ESG4.0 / 5Environmental Score-1.95 Percentage of Shares Shorted2.14% of the outstanding shares of Baxter International have been sold short.Short Interest Ratio / Days to CoverBaxter International has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Baxter International has recently increased by 24.60%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.39 News SentimentBaxter International has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Baxter International this week, compared to 7 articles on an average week.Search InterestOnly 13 people have searched for BAX on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Baxter International to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Baxter International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.21% of the stock of Baxter International is held by insiders.Percentage Held by Institutions90.19% of the stock of Baxter International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Baxter International's insider trading history. BAX Stock News Headlines5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025September 19 at 8:12 AM | seekingalpha.comBaxter International (NYSE:BAX) Upgraded at StockNews.comSeptember 17 at 3:15 AM | americanbankingnews.comChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . September 19, 2024 | True Gold Republic (Ad)Exeter Chiefs: Rob Baxter delivers frank assessment on Welsh international who ‘disappointed’ him previouslySeptember 16 at 10:00 PM | msn.comLaGrange College President gives State of the College AddressSeptember 13, 2024 | msn.comBrokerages Set Baxter International Inc. (NYSE:BAX) Target Price at $41.73September 13, 2024 | americanbankingnews.comBaxter International Inc. stock rises Wednesday, still underperforms marketSeptember 11, 2024 | marketwatch.comStockNews.com Downgrades Baxter International (NYSE:BAX) to HoldSeptember 11, 2024 | americanbankingnews.comSee More Headlines BAX Stock Analysis - Frequently Asked Questions How have BAX shares performed this year? Baxter International's stock was trading at $38.66 at the beginning of 2024. Since then, BAX shares have increased by 2.3% and is now trading at $39.54. View the best growth stocks for 2024 here. How were Baxter International's earnings last quarter? Baxter International Inc. (NYSE:BAX) posted its earnings results on Tuesday, August, 6th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.02. Baxter International's revenue was up 2.8% on a year-over-year basis. Read the conference call transcript. Does Baxter International have any subsidiaries? Baxter International subsidiaries include Cheetah Medical, ApaTech Limited, Baxter AO, Baxter Belgium SPRL, Baxter (China) Investment Co. Ltd, Baxter Company Ltd, Baxter Corporation (Canada), and more. Who are Baxter International's major shareholders? Baxter International's top institutional shareholders include Bank of New York Mellon Corp (1.33%), LSV Asset Management (0.82%), Shapiro Capital Management LLC (0.64%) and Thompson Siegel & Walmsley LLC (0.39%). Insiders that own company stock include Jeanne K Mason, Albert P L Stroucken, Jacqueline Kunzler and Brian Stevens. View institutional ownership trends. How do I buy shares of Baxter International? Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Baxter International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Baxter International investors own include Xtrackers California Municipal Bond ETF (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC) and Abbott Laboratories (ABT). Company Calendar Ex-Dividend for 7/1 Dividend5/31/2024Dividend Payable7/01/2024Last Earnings8/06/2024Ex-Dividend for 10/1 Dividend8/30/2024Today9/19/2024Dividend Payable10/01/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:BAX CUSIP07181310 CIK10456 Webwww.baxter.com Phone(224) 948-2000Fax224-948-1813Employees60,000Year Founded1931Price Target and Rating Average Stock Price Target$41.73 High Stock Price Target$54.00 Low Stock Price Target$30.00 Potential Upside/Downside+6.7%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$5.20 Trailing P/E Ratio7.52 Forward P/E Ratio13.21 P/E Growth1.33Net Income$2.66 billion Net Margins16.51% Pretax Margin-0.50% Return on Equity18.06% Return on Assets5.21% Debt Debt-to-Equity Ratio1.35 Current Ratio1.40 Quick Ratio0.91 Sales & Book Value Annual Sales$15.00 billion Price / Sales1.33 Cash Flow$5.22 per share Price / Cash Flow7.49 Book Value$16.69 per share Price / Book2.34Miscellaneous Outstanding Shares509,580,000Free Float508,510,000Market Cap$19.92 billion OptionableOptionable Beta0.59 Social Links Should I Buy Baxter International Stock? BAX Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 8, 2024. Please send any questions or comments about these Baxter International pros and cons to contact@marketbeat.com. Baxter International Bull Case Here are some ways that investors could benefit from investing in Baxter International Inc.: Baxter International Inc. has shown consistent revenue growth over the past few quarters, indicating a strong financial performance. The company's dividend yield of 3.06% provides investors with a steady income stream, making it an attractive option for income-oriented investors. Recent upgrades in stock ratings from "hold" to "buy" by reputable sources like StockNews.com could signal positive momentum and potential stock price appreciation. Baxter International Inc.'s current stock price of $36.91 presents a potential buying opportunity for investors looking to enter at a relatively lower price point. The company's diversified portfolio of healthcare products across different segments provides stability and resilience in varying market conditions. Baxter International Bear Case Investors should be bearish about investing in Baxter International Inc. for these reasons: Analysts have downgraded Baxter International Inc.'s stock rating to "underweight," indicating potential concerns about the company's future performance. The company's stock has experienced a recent decline of 0.6%, suggesting short-term volatility and potential risks for investors. With a debt-to-equity ratio of 1.35, Baxter International Inc. carries a moderate level of debt, which could impact its financial flexibility and risk profile. Despite positive earnings results, the company's stock price has not shown significant growth, raising questions about its ability to deliver strong returns to investors. Market analysts have set a consensus target price of $41.73 for Baxter International Inc.'s stock, indicating limited upside potential based on current valuations. This page (NYSE:BAX) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Baxter International Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Baxter International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.